[1] ZHOU S F, LIU J P, CHOWBAY B. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev, 2009,41(2):89-95.
[2] STROM C M, GOOS D, CROSSLEY B, et al. Testing for variants in CYP2C19:population frequencies and testing experience in a clinical laboratory[J]. Genet Med, 2012, 14(1):95-100.
[3] OWUSU OBENG A, EGELUND E F, ALSULTAN A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole:are we ready for clinical implementation of pharmacogenomics[J]. Pharmacotherapy, 2014,34(7):703-718.
[4] 刘文忠, 谢勇, 陆红,等. 第五次全国幽门螺旋杆菌感染处理共识报告[J]. 中国实用内科杂志,2017,37(6):509-524.
[5] LEJA M, AXON A, BRENNER H. Epidemiology of Helicobacter pylori infection[J]. Helicobacter,2016,21(Suppl 1):3-7.
[6] SONNENBERG A, LASH R H, GENTA R M. A national study of Helicobactor pylori infection in gastric biopsy specimens[J]. Gastroenterology, 2010,139(6):1894-1901.
[7] 缪亚军,杨莉. 紫杉醇联合顺铂调控MAPK/NF-κB信号治疗幽门螺杆菌胃癌机制的研究[J].东南大学学报(医学版),2018,37(4):706-710.
[8] SUGANO K, TACK J, KUIPERS E J, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015,64(9):1353-1367.
[9] DELLA MONICA P, LAVAGNA A, MASOERO G, et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy[J]. Aliment Pharmacol Ther, 2002,16(6):1269-1275.
[10] KUO C H, KUO F C, HU H M, et al. The optimal first-line therapy of Helicobacter pylori infection in year 2012[J]. Gastroenterol Res Pract,2012,17(3):357-361.
[11] GISBERT J P. Potent gastric acid inhibition in Helicobacter pylori eradication[J]. Drugs,2005,65(10):83-96.
[12] 李晓敏, 余霞霞. 合理用药干预对外科预防性使用质子泵抑制剂的影响[J].东南大学学报(医学版), 2019,38(1):43-46.
[13] GOLDSTEIN J A, ISHIZAKI T, CHIBA K, et al. Frequencies of the detective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations[J]. Pharmacogenetics,1997,16(7):59-64.
[14] IEIRI I, KUBOTA T, URAE A, et al. Pharmacokinetics of omeprazole (a subject of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects[J]. Clin Pharmacol Ther,1996,59(11):647-653.
[15] YAMADA S, ONDA M, KATO S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J]. J Gastroenterol, 2001, 36(10):669-672.
[16] 周健, 吕虹, 康熙雄. 中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J]. 中国临床药理学与治疗学, 2007,12(2):208-213.
[17] 蒋兴然, 张云岗, 路军, 等.北方地区汉族消化道疾病中CYP2C19基因多态性分析[J]. 临床与实验病理学杂志, 2016,32(10):1101-1109.
[18] 李传保, 戴大鹏, 蔡杰, 等.中国汉族人群24种CYP2C19新突变体的体外活性研究[J]. 山西医科大学学报, 2015,46(5):428-433.
[19] SUGIMOTO M, UOTANI T, SAHARA S, et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion[J]. Helicobacter,2014,19(10):312-318. |